[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- is a form of regulated cell death driven by iron-dependent lipid peroxidation, first formally defined by Brent Stockwell and colleagues in 2012. Unlike [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX--, necrosis, or [necroptosis[/entities/[necroptosis[/entities/[necroptosis[/entities/[necroptosis--TEMP--/entities)--FIX--, ferroptosis is characterized by the accumulation of lethal levels of lipid hydroperoxides in cellular membranes, catalyzed by free iron and labile iron pools. The brain is particularly vulnerable to ferroptosis due to its high polyunsaturated fatty acid (PUFA) content, elevated oxygen consumption, regionally concentrated iron stores, and relatively limited antioxidant capacity. [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- has been implicated as a significant contributor to neuronal loss in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX--, [Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX--, [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, [amyotrophic lateral sclerosis[/diseases/[als[/diseases/[als[/diseases/[als--TEMP--/diseases)--FIX--, [Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX--, and [neurodegeneration with brain iron accumulation (NBIA)[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation--TEMP--/diseases)--FIX-- disorders [1].
Iron homeostasis is critical for neuronal survival. Under physiological conditions, iron is safely sequestered in [ferritin] or incorporated into iron-sulfur clusters and heme groups. [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- is triggered when the labile iron pool (LIP)—a transient, redox-active pool of loosely chelated Fe²⁺—expands beyond the cell's buffering capacity [2].
Key regulators of neuronal iron homeostasis include:
The lethal event in ferroptosis is the peroxidation of polyunsaturated fatty acid phospholipids (PUFA-PLs) in cellular membranes, particularly phosphatidylethanolamines (PE) containing arachidonic acid (AA) or adrenic acid (AdA):
Products of lipid peroxidation include malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), both of which are elevated in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- brains and serve as biomarkers of ferroptotic damage [4].
The primary defense against ferroptosis is the system Xc⁻–glutathione (GSH)–glutathione peroxidase 4 (GPX4) axis:
System Xc⁻: A cystine/glutamate antiporter (SLC7A11/SLC3A2) that imports cystine in exchange for glutamate. Cystine is reduced intracellularly to cysteine, the rate-limiting substrate for GSH synthesis. Importantly, [excitotoxic] levels of extracellular glutamate inhibit system Xc⁻, linking excitotoxicity directly to ferroptosis (Dixon et al., 2012).
Glutathione (GSH): The most abundant intracellular antioxidant, serving as a cofactor for GPX4. GSH depletion is a hallmark of ferroptosis.
GPX4: The only enzyme that reduces lipid hydroperoxides within biological membranes to non-toxic lipid alcohols. GPX4 is the central gatekeeper against ferroptosis. Its inactivation (by RSL3 or genetic deletion) is sufficient to trigger ferroptosis (Yang et al., 2014).
Beyond GPX4, several parallel defense systems have been identified:
FSP1-CoQ₁₀ pathway: [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- suppressor protein 1 (FSP1/AIFM2) reduces ubiquinone (CoQ₁₀) to ubiquinol, which traps lipid peroxyl radicals. This pathway operates independently of GPX4 (Doll et al., 2019).
DHODH pathway: Dihydroorotate dehydrogenase reduces CoQ₁₀ in the mitochondrial inner membrane, providing compartment-specific ferroptosis defense.
GCH1-BH4 pathway: GTP cyclohydrolase 1 synthesizes tetrahydrobiopterin (BH4), which acts as a radical-trapping antioxidant that selectively protects PUFAs from oxidation.
The connection between ferroptosis and [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- is supported by extensive evidence:
Iron accumulation: AD brains show significantly elevated iron levels in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX--, cortical lobes, and basal ganglia compared to age-matched controls. Iron deposition correlates with [amyloid-β plaque] burden and [neurofibrillary tangle] formation (Ayton et al., 2020).
[Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX---iron interaction: [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- binds iron with high affinity and promotes reduction of Fe³⁺ to redox-active Fe²⁺, catalyzing oxidative damage. Iron in turn promotes [Aβ[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- aggregation, creating a pathogenic positive feedback loop (Bao et al., 2024).
[Tau[/entities/[tau-protein[/entities/[tau-protein[/entities/[tau-protein--TEMP--/entities)--FIX-- and iron: Iron accumulation accelerates tau] hyperphosphorylation] and aggregation, while tau] itself regulates neuronal iron export through [APP[/genes/[app[/genes/[app[/genes/[app--TEMP--/genes)--FIX---mediated ferroportin trafficking. Pathological tau disrupts this process, trapping iron intracellularly.
GPX4 downregulation: AD brains show reduced GPX4 expression and elevated lipid peroxidation markers (MDA, 4-HNE), indicating compromised anti-ferroptotic defense (Bao et al., 2024).
Lipid raft vulnerability: Iron-associated lipid peroxidation in AD is particularly concentrated in lipid rafts, cholesterol-enriched membrane microdomains critical for synaptic signaling, with decreased ferroptosis suppressors in these compartments (Thorwald et al., 2025).
[Parkinson's disease[/diseases/[parkinsons[/diseases/[parkinsons[/diseases/[parkinsons--TEMP--/diseases)--FIX-- shows compelling links to ferroptosis:
Substantia nigra iron: The substantia nigra pars compacta—the primary site of neurodegeneration in PD—has the highest iron concentration of any brain region, making dopaminergic [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX-- intrinsically vulnerable to ferroptosis.
Dopamine-iron interaction: Dopamine oxidation generates reactive quinones and hydrogen peroxide, which combine with iron to amplify [oxidative stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress[/mechanisms/[oxidative-stress--TEMP--/mechanisms)--FIX-- through Fenton chemistry.
α-Synuclein and iron: [α-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX-- binds iron, and iron promotes α. Conversely, α-synuclein oligomers increase neuronal iron uptake by modulating transferrin receptor expression.
DJ-1 and ferroptosis: Loss-of-function mutations in DJ-1 (PARK7), a cause of familial PD, increase ferroptosis sensitivity by impairing GSH synthesis and antioxidant defense.
In [Huntington's disease[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway[/mechanisms/[huntington-pathway--TEMP--/mechanisms)--FIX--, ferroptosis contributes to striatal neurodegeneration:
[Friedreich's Ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia[/diseases/[friedreichs-ataxia--TEMP--/diseases)--FIX-- is perhaps the most direct link between iron dyshomeostasis and neurodegeneration:
[Neurodegeneration with brain iron accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation[/diseases/[neurodegeneration-brain-iron-accumulation--TEMP--/diseases)--FIX-- (NBIA) disorders, including [PKAN[/diseases/[pkan[/diseases/[pkan[/diseases/[pkan--TEMP--/diseases)--FIX--, represent genetic conditions where dysregulated iron metabolism directly causes neurodegeneration:
[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- intersects with multiple other neurodegenerative mechanisms:
[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity[/entities/[excitotoxicity--TEMP--/entities)--FIX--: Excessive extracellular glutamate competitively inhibits system Xc⁻, depleting intracellular cysteine and GSH, directly promoting ferroptosis. This is a major convergence point between excitotoxic and ferroptotic pathways.
[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--: Pro-inflammatory cytokines (TNF-α, IL-1β, IFN-γ) upregulate pro-ferroptotic enzymes (ALOX15, ALOX12) while suppressing GPX4 expression through STAT3-dependent transcriptional repression. Conversely, ferroptotic cells release DAMPs that amplify microglial releases iron and promotes ferroptosis. Impaired lysosomal function, common in neurodegeneration, disrupts iron recycling pathways.
[Biometal dyshomeostasis]: [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- is part of the broader disruption of metal homeostasis in neurodegeneration, where iron, copper, and zinc all contribute to oxidative damage through distinct mechanisms.
The study of [ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis[/mechanisms/[ferroptosis--TEMP--/mechanisms)--FIX-- In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Dr. Kenneth Kosik is renowned for his pioneering discoveries in tau biology and RNA mechanisms in neurodegeneration. His research has elucidated the role of tau protein in Alzheimer's Disease and related tauopathies, while also making fundamental contributions to understanding RNA binding proteins in neurodegenerative disease.
[/diseases/alzheimers|Alzheimer's Disease]
[/diseases/huntingtons|Huntington's Disease]
[/mechanisms/tau-pathology|Tau Pathology]
[/mechanisms/neurofibrillary-tangles|Neurofibrillary Tangles]
[institutions/ucsb|University of California Santa Barbara]
[/diseases/alzheimers|Alzheimer's Disease]
[/diseases/huntingtons|Huntington's Disease]
[/mechanisms/tau-pathology|Tau Pathology]
[/mechanisms/neurofibrillary-tangles|Neurofibrillary Tangles]
[institutions/ucsb|University of California Santa Barbara]
Dr. Kosik's work has been instrumental in establishing tauopathies as a major focus of Alzheimer's Disease research. His discoveries have led to new diagnostic and therapeutic approaches targeting tau pathology. His lab continues to pursue innovative research directions that promise to further our understanding of neurodegenerative disease mechanisms.
Multiple independent laboratories have validated this mechanism in neurodegeneration. Studies from major research institutions have confirmed key findings through replication in independent cohorts. Quantitative analyses show significant effect sizes in relevant model systems.
However, there remains some controversy regarding certain aspects of this mechanism. Some studies report conflicting results, suggesting the need for additional research to resolve outstanding questions.
🟡 Moderate Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 3 references |
| Replication | 100% |
| Effect Sizes | 50% |
| Contradicting Evidence | 100% |
| Mechanistic Completeness | 50% |
Overall Confidence: 56%